Rationale: Basiliximab and etanercept have achieved promising responses in steroid-refractory graft versus host disease (SR-GVHD). However, the in vivo immune changes following the treatment have not been elucidated.
Introduction
Treatment options for steroid-refractory graft versus host disease (SR-GVHD) are limited and the prognosis is poor. [1] Inflammatory cytokines are important mediators of GVHD, and may be critical targets for therapy. [2] Our previous study showed that the combination of a CD25 monoclonal antibody (basiliximab) with a recombinant tumor necrosis factor (TNF) receptor/immunoglobulin G fusion protein (etanercept) induced a high response rate in patients with severe SR-GVHD; [3] however, the in vivo changes following the treatment with basiliximab and etanercept have not been elucidated. We herein report an unusual case of long-lasting expansion of donor-derived CD3 + CD56 + natural killer T (NKT)-like cells after treatment of SR-GVHD with basiliximab and etanercept.
Case presentation
A 14-year-old boy was diagnosed with high-risk acute lymphocytic leukemia (ALL) and relapsed after 3 cycles of intensive chemotherapy on the Chinese ALL 2005 protocol. [4] He achieved complete remission after chemotherapy, which consisted of idarubicin, vincristine, dexamethasone, and pegaspargase. He then underwent a peripheral blood stem cell transplantation from his human leukocyte antigen-haploidentical mother. The conditioning regimen consisted of cytarabine (4 + NKT-like cells reached a peak value of 37%, and decreased slightly thereafter (Fig. 1, A and B) . Chimerism analysis using short tandem repeats after cell sorting showed that the expanded NKT cells were complete donor chimerism and a PCR assay showed no evidence of clonal T-cell antigen receptor (TCR) gene rearrangement. CD3 + CD56 + NKT-like cells are a broad group of CD3 + T cells coexpressing TCR and NK-cell markers, sharing both NK and T cell characteristics. Studies have shown an altered quantity and quality of CD3 + CD56 + NKT-like cells in patients with leukemia or other cancers; [5, 6] however, the function and clinical relevance of + cells in this patient, so we analyzed the serum levels of interferon gamma (IFN-g), interleukin 2(IL-2), and IL-15 at several time points. The serum levels of IFN-g, IL-2, and IL-15 significantly increased at the time of GVHD. After GVHD was controlled, serum IL-2 and IL-15 levels decreased to baseline; however, serum IFN-g levels decreased slightly after the treatment, but increased again and reached a second peak of 72.3 pg/mL 8 weeks after treatment, which coincided with the maximum number of CD3 + CD56 + NKT-like cells (Fig. 1 , B and C). Simultaneously, we collected lymphocytes from the patient and his mother (the donor) 8 weeks after the anticytokine treatment for IFN-g production assay and noted a completely different model of IFN-g production by the 3 subgroups of lymphocytes from the patient and his mother (Fig. 1, D Fig. 2C ) and compared the cytotoxicity against an acute lymphocytic leukemia cell line (Reh cells) by a flow cytometric cytotoxicity assay. [7] NKT-like cells showed more potent cytotoxicity against Reh cells than T cells, and nearly matched the most potent killer NK cells (Fig. 2D) . Similar results were observed using a degranulation assay (Fig. 2E) .
Given that the expansion of functional CD3 + CD56 + NKT-like cells lasted > 2 years and the patient had a leukemia-free survival 
Discussion
Kim et al [8] reported that large granular lymphocytosis could be detected in approximately 20% of recipients after allogeneic HSCT(allo-HSCT), and might lead to a favorable outcome and low risk of relapse; however, expansion of CD3 + CD56 + NKT cells is rarely reported in recipients of allo-HSCT, [9] and to our knowledge, this is the first report of long-lasting expansion of CD3 + CD56
+ NKT cells after control of SR-GVHD with anticytokine treatment. In this case, NKT cell expansion generated gradually after the period of lymphocytopenia caused by GVHD and anticytokine therapy in association with fluctuating serum cytokines. Although the underlying mechanism could not be determined, we presume that the fluctuating serum cytokines and the contraction of donor-derived T-cell proliferation by basiliximab and etanercept contributes to NKT cell expansion. CD3 + CD56 + NKT cells represent only 2.94% ± 1.49% of lymphocytes in the peripheral blood of healthy adults and approximately 5.63% ± 2.93% of peripheral blood lymphocytes of allo-HSCT recipients 12 weeks after transplantation (unpublished data). Numerous studies have confirmed that CD3 + CD56 + NKT cells can be generated in vitro using exogenous IL-2, IL-15, IFN-g, and anti-CD3, [10] while several reports have detected in vivo expansion of CD3 + CD56
+ NKT cells in special situations. [9, 11] Kishi et al [9] reported a case of peripheral CD3 + CD56 + T-cell expansion in hyperacute GVHD and presumed the cytokine storm in hyperacute GVHD might promote the generation of CD3 + CD56 + NKT cells. We found that the serum levels of IL-2, IFN-g, and IL-15, which played important roles in the proliferation and cytotoxicity of NKT cells, were elevated significantly during GVHD and decreased after the control of GVHD. Interestingly, serum levels of IFN-g did not return to baseline. IFN-g has been shown to play critical roles in the proliferation and cytotoxicity of NKT cells in several studies. [12, 13] Okita et al [14] reported that basiliximab augments IFNg production by activated peripheral blood mononuclear cells. Similarly, we found a higher level of IFN-g production by NKT and T cells in the current patient than his healthy mother, which www.md-journal.com might contribute to the persistent high serum IFN-g level and supported the persistent proliferation and potent cytotoxicity of NKT cells. The combined treatment with basiliximab and etanercept might restrict the proliferation of allogeneic reactive and normal T cells, while taking advantage of the proliferation of NKT cells responding to the increased serum cytokines. Basiliximab, also known as anti-CD25, binds the high-affinity a-chain of the IL-2 receptor (IL-2R), thereby inhibiting high-affinity IL-2R signaling, but not intermediate-affinity IL-2R signaling.
[15] Therefore, we reasoned that basiliximab might deprive IL-2 from high-affinity IL-2R signaling in activated T cells, while increasing IL-2 availability for intermediate-affinity IL-2R signaling in NK and NKT cells, warranting the priority of innate immune cell proliferation. It has been reported that anti-CD25 therapy by daclizumab leads to expansion of CD56 bright NK cells in patients with multiple sclerosis; [16, 17] however, similar results have not been reported in GVHD patients.
Taken together, we propose 3 essential factors, as follows: the cytokine storm induced by GVHD; the persistent high serum IFN-g levels by autocrine NKT and paracrine NK and T cells; and the potent inhibition of adaptive T-cell immunity by combined anticytokine treatment, might have led to the predilection for functional NKT cell expansion in this case. Therefore, this preliminary data might open the door to explore the hypotheses generated in this single case. Further studies are needed to explore the underlining mechanism of cytokine surges and lymphocytic subsets changes after the combination of basiliximab and etanercept for GVHD patients in the context of allo-HSCT.
Conclusions
We described the first time that long-lasting expansion of CD3 + CD56 + NKT was in association with fluctuating serum cytokines after anticytokine therapy in a case of SR-GVHD. Although the underlying mechanism could not be determined in a single case, our case warrants further studies to explore the roles of cytokines and NKT-like cells after anticytokine treatments for GVHD patients.
